Journal Article

New agents active against <i>Mycobacterium avium</i> complex selected by molecular topology: a virtual screening method

Ángeles García-García, Jorge Gálvez, Jesus-Vicente de Julián-Ortiz, Ramón García-Domenech, Carlos Muñoz, Remedios Guna and Rafael Borrás

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 1, pages 65-73
Published in print January 2004 | ISSN: 0305-7453
Published online January 2004 | e-ISSN: 1460-2091 | DOI:
New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


Objectives: In order to select new drugs and to predict their in vitro activity against Mycobacterium avium complex (MAC), new quantitative structure–activity relationship (QSAR) models were developed.

Methods: The activities against MAC of 29 structurally heterogeneous drugs were examined by means of linear discriminant analysis (LDA) and multilinear regression analysis (MLRA) by using topological indices (TI) as structural descriptors. In vitro antimycobacterial activities were determined by a broth microdilution method with 7H9 medium.

Results: The topological model obtained successfully classifies over 80% of compounds as active or inactive; consequently, it was applied in the search for new molecules active against MAC. From among the selected candidates demonstrating in vitro activity, aflatoxin B1, benzalkonium chloride and pentamidine stand out, with MIC50s between 4 and 32 mg/L.

Conclusion: The method described in this work is able to select molecules active against MAC.

Keywords: Keywords: MAC, QSAR studies, topological indices

Journal Article.  5660 words.  Illustrated.

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.